Refine
Year of publication
Document Type
- Article (43)
Language
- English (43) (remove)
Has Fulltext
- yes (43)
Is part of the Bibliography
- no (43)
Keywords
- HIV (4)
- COVID-19 (2)
- Opportunistic infections (2)
- SARS-CoV-2 (2)
- AA-amylodosis (1)
- Acute coronary syndrome (1)
- Antibody avidity (1)
- Antigens (1)
- Antiretroviral therapy (1)
- Assay variation (1)
- Atrial fibrillation (1)
- B cell subpopulations (1)
- BPTF (1)
- Blood groups (1)
- COBAS Taqman (1)
- CVID (1)
- Cancer (1)
- Cancer genetics (1)
- Cancer genomics (1)
- Cardiac troponin (1)
- Cardiovascular biology (1)
- Cerebral toxoplasmosis HIV (1)
- Chemorefractory advanced gastric cancer (1)
- Children (1)
- Chronic kidney disease (1)
- Culture positive (1)
- De-isolation (1)
- Decision trees (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- FAPI PET (1)
- FOLFIRI (1)
- Filariosis (1)
- First-line combination antiretroviral therapy (1)
- First-line regimen (1)
- GIIb/IIIa-receptor (1)
- Genomic instability (1)
- German PID-NET registry (1)
- HCV (1)
- HIV protease inhibitors (1)
- HIV-RNA (1)
- HSP (hereditary spastic paraplegia) (1)
- Haplotypes (1)
- Hemophilia A (1)
- Human genetics (1)
- IVDU (1)
- IgG substitution therapy (1)
- KLHL11 (1)
- Late presentation (1)
- Loa loa (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Microfilaremia (1)
- Migrant health (1)
- Molecular medicine (1)
- Mycobacteria (1)
- Mycobacterium avium complex (1)
- Myocardial infarction (1)
- N471D strumpellin knock-in mice (1)
- NTDs (1)
- NURF (1)
- Neglected tropical diseases (1)
- Nontuberculous mycobacteria (1)
- Open pulmonary tuberculosis (1)
- PAC-1 (1)
- PCP (1)
- PID prevalence (1)
- Persistence SARS-CoV-2 antibodies (1)
- Phylogenetic analysis (1)
- Pneumocystis jirovecii (1)
- Pre-treatment drug resistance mutations (1)
- Protease inhibitor therapy (1)
- RealTime (1)
- Respiratory infections (1)
- SPG8 (1)
- Sensitivity (1)
- Specificity (1)
- Sputum smear-negative (1)
- Sunitinib (1)
- T cell response (1)
- TB-therapy (1)
- Treatment (1)
- Treatment modification (1)
- Trees (1)
- Tyrosine kinase inhibitor (1)
- VEGF (1)
- Viral load (1)
- Virological failure (1)
- WASH complex subunit 5 (1)
- animal experiments (1)
- anti-retroviral agents (1)
- autoimmunity (1)
- biomarker (1)
- blood hiv rna (1)
- booster (1)
- cART (1)
- cardiac magnetic resonance (1)
- cd4 count determination procedure (1)
- chronic kidney disease (1)
- cirrhosis (1)
- clinical immunology (1)
- cohort study (1)
- death rates (1)
- decision aids (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- epidemiology (1)
- exponential model (1)
- fibrosis imaging (1)
- flow cytometry (1)
- guidelines (1)
- hemodialysis (1)
- hiv (1)
- human immunodeficiency virus (1)
- immunosuppression (1)
- infection (1)
- intranasal administration (1)
- leucocytes (1)
- liver transplantation (1)
- lymphocytes (1)
- mRNA-1273 (1)
- medical risk factors (1)
- mice (1)
- monoclonal antibody (1)
- mortality risk (1)
- myocardial fibrosis (1)
- neutralization (1)
- neutralizing antibody (1)
- non-ST-segment elevation acute coronary syndrome (1)
- nuclear cardiology (1)
- perinatal HIV infection (1)
- platelets (1)
- pneumocystis (1)
- pneumocystis carinii (1)
- pneumocystis pneumonia (1)
- pneumonia (1)
- prevention (1)
- primary immunodeficiency (PID) (1)
- prophylaxis (1)
- pseudomonas aeruginosa (1)
- reference values (1)
- registry for primary immunodeficiency (1)
- renal transplantation (1)
- risk factors (1)
- scar (1)
- seroconversion (1)
- strumpellin (1)
- survival (1)
- topical administration (1)
- transduction (1)
- transplantation (1)
- vaccination (1)
- virological failure (1)
- virus (1)
- young people (1)
Institute
- Medizin (43) (remove)
Poster presentation: Purpose of the study The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to the saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of PI-experienced, but SQV-naïve patients. ...
Poster presentation: Purpose of the study The aim of the Rainbow Cohort is to assess the tolerability and efficacy of initiating treatment with, or switching treatment to saquinavir (SQV) 500 mg film-coated tablet formulation. We present the final 48-week subgroup analysis of antiretroviral therapy (ART)-naïve patients. ...
Poster presentation: Purpose of the study To compare the virological, immunological and clinical response to three boosted double protease inhibitor (PI) regimens of saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprenavir (FOSAQ) without reverse transcriptase inhibitors (RTI) in HIV-positive patients with limited RTI treatment options. ...
Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or fosamprenavir (FOSAQ) in HIV-positive patients, treated without reverse transcriptase inhibitors (RTI). ...
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC.
Methods: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m2 cyclophosphamide (CP) 3 days before first L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 mug once weekly for 8 weeks, followed by s.c. L-BLP25 930 mug maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety, tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study will provide recurrence-free and overall survival rates of groups in an unbiased fashion. Trial Registration EudraCT Number 2011-000218-20
Background: To perform a comprehensive study on the relationship between vitamin D metabolism and the response to interferon-α-based therapy of chronic hepatitis C.
Methodology/Principal Findings: Associations between a functionally relevant polymorphism in the gene encoding the vitamin D 1α-hydroxylase (CYP27B1-1260 rs10877012) and the response to treatment with pegylated interferon-α (PEG-IFN-α) and ribavirin were determined in 701 patients with chronic hepatitis C. In addition, associations between serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3) and treatment outcome were analysed. CYP27B1-1260 rs10877012 was found to be an independent predictor of sustained virologic response (SVR) in patients with poor-response IL28B genotypes (15% difference in SVR for rs10877012 genotype AA vs. CC, p = 0.02, OR = 1.52, 95% CI = 1.061–2.188), but not in patients with favourable IL28B genotype. Patients with chronic hepatitis C showed a high prevalence of vitamin D insufficiency (25[OH]D3<20 ng/mL) during all seasons, but 25(OH)D3 serum levels were not associated with treatment outcome.
Conclusions/Significance: Our study suggests a role of bioactive vitamin D (1,25[OH]2D3, calcitriol) in the response to treatment of chronic hepatitis C. However, serum concentration of the calcitriol precursor 25(OH)D3 is not a suitable predictor of treatment outcome.
Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Methods: Retrospective investigation including all patients with prior or present IVDU that underwent renal biopsy because of chronic kidney disease between 01.04.2002 and 31.03.2012 in the city of Frankfurt/Main, Germany.
Results: Twenty four patients with IVDU underwent renal biopsy because of progressive chronic kidney disease or proteinuria. Renal AA-amyloidosis was the predominant cause of renal failure in 50% of patients. Membranoproliferative glomerulonephritis (GN) was the second most common cause found in 21%. Patients with AA-amyloidosis were more likely to be HIV infected (67 vs.17%; p=0.036) and tended to have a higher rate of repeated systemic infections (92 vs. 50%; p=0.069). Patients with AA-amyloidosis presented with progressive renal disease and nephrotic-range proteinuria but most patients had no peripheral edema or systemic hypertension. Development of proteinuria preceded the decline of GFR for approximately 1--2 years.
Conclusions: AA-amyloidosis was the predominant cause of progressive renal disease in the last 10 years in patients with IVDU. The highest rate of AA-amyloidosis observed was seen in HIV infected patients with IVDU. We speculate that chronic HIV-infection as well as the associated immunosuppression might promote development of AA-amyloidosis by increasing frequency and duration of infections acquired by IVDU.
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.
Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine.
Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare.
Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over TDF alone.
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study
(2013)
Background: Despite advances in HIV treatment, bacterial pneumonia continues to cause considerable morbidity and mortality in patients with HIV infection. Studies of biomarker associations with bacterial pneumonia risk in treated HIV-infected patients do not currently exist.
Methods: We performed a nested, matched, case-control study among participants randomized to continuous combination antiretroviral therapy (cART) in the Strategies for Management of Antiretroviral Therapy trial. Patients who developed bacterial pneumonia (cases) and patients without bacterial pneumonia (controls) were matched 1:1 on clinical center, smoking status, age, and baseline cART use. Baseline levels of Club Cell Secretory Protein 16 (CC16), Surfactant Protein D (SP-D), C-reactive protein (hsCRP), interleukin-6 (IL-6), and d-dimer were compared between cases and controls.
Results: Cases (n = 72) and controls (n = 72) were 25.7% female, 51.4% black, 65.3% current smokers, 9.7% diabetic, 36.1% co-infected with Hepatitis B/C, and 75.0% were on cART at baseline. Median (IQR) age was 45 (41, 51) years with CD4+ count of 553 (436, 690) cells/mm3. Baseline CC16 and SP-D were similar between cases and controls, but hsCRP was significantly higher in cases than controls (2.94 µg/mL in cases vs. 1.93 µg/mL in controls; p = 0.02). IL-6 and d-dimer levels were also higher in cases compared to controls, though differences were not statistically significant (p-value 0.06 and 0.10, respectively).
Conclusions: In patients with cART-treated HIV infection, higher levels of systemic inflammatory markers were associated with increased bacterial pneumonia risk, while two pulmonary-specific inflammatory biomarkers, CC16 and SP-D, were not associated with bacterial pneumonia risk.
RP1 (synonym: MAPRE2, EB2) is a member of the microtubule binding EB1 protein family, which interacts with APC, a key regulatory molecule in the Wnt signalling pathway. While the other EB1 proteins are well characterized the cellular function and regulation of RP1 remain speculative to date. However, recently RP1 has been implicated in pancreatic cancerogenesis. CK2 is a pleiotropic kinase involved in adhesion, proliferation and anti-apoptosis. Overexpression of protein kinase CK2 is a hallmark of many cancers and supports the malignant phenotype of tumor cells. In this study we investigate the interaction of protein kinase CK2 with RP1 and demonstrate that CK2 phosphorylates RP1 at Ser236 in vitro. Stable RP1 expression in cell lines leads to a significant cleavage and down-regulation of N-cadherin and impaired adhesion. Cells expressing a Phospho-mimicking point mutant RP1-ASP236 show a marked decrease of adhesion to endothelial cells under shear stress. Inversely, we found that the cells under shear stress downregulate endogenous RP1, most likely to improve cellular adhesion. Accordingly, when RP1 expression is suppressed by shRNA, cells lacking RP1 display significantly increased cell adherence to surfaces. In summary, RP1 phosphorylation at Ser236 by CK2 seems to play a significant role in cell adhesion and might initiate new insights in the CK2 and EB1 family protein association.